TerminatedPhase 2NCT00374296
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mirati Therapeutics Inc.
- Principal Investigator
- Gregory Reid, MSc, MBAMethylGene Inc.
- Intervention
- MGCD0103(drug)
- Enrollment
- 35 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2008
Study locations (13)
- Veterans Affairs Medical Center, Kansas City, Missouri, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Gabrail Cancer Center, Canton, Ohio, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Ohio State University Medical Center - James Cancer Hospital, Columbus, Ohio, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Hamilton Health Sciences - McMaster Hospital, Hamilton, Ontario, Canada
- UHN - Princess Margaret Hospital, Toronto, Ontario, Canada
- Hopital Charles Lemoyne, Greenfield Park, Quebec, Canada
- Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
- Hopital Notre-Dame du CHUM, Montreal, Quebec, Canada
- Sir Mortimer Davis-Jewish General Hospital, Montreal, Quebec, Canada
- Universite de Sherbrooke, Service d'hematologie, Sherbrooke, Quebec, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00374296 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute